MARKHAM, ON, Nov. 18, 2016
Research applications now being accepted for the 2017 competition
MARKHAM, ON, Nov. 18, 2016 /CNW/ - The Canadian Urological Association (CUA) and Astellas Pharma Canada, Inc. (Astellas) are pleased to announce the renewal of the CUA Astellas Research Grant Program for an additional three years.
The research grant program was originally launched in 2012, initiating a five year commitment to support scientific discovery and innovation within the urologic scientific community. With this renewed commitment, Astellas pledges an additional $450,000 over three years to continue to support Canadian peer-reviewed research in urology, with the ultimate goal of improving patient care.
The primary focus of the program is to support research in the area of functional urology such as over active bladder (OAB), lower urinary tract symptoms (LUTS), pelvic floor disorders, voiding dysfunctions, and neurogenic bladder. Secondary areas of focus could include other urological areas such as community-based research, practice improvement, multidisciplinary management, basic research, etc. Grant recipients are expected to demonstrate improved understanding of their specific research area and/or contribute to improving patient care.
"The Canadian Urological Association Scholarship Foundation (CUASF) is very thankful and relies on the continued support from Astellas to provide critical funding for our members of the CUA involved in research in areas of functional urology," said Dr. Jonathan Izawa, chair of the CUASF scientific council.
"We are proud to continue our support of the CUA Astellas Research Grant Program and through it, promising advances in urology research that can result in better outcomes for patients," said Fran Paradiso-Hardy, Senior Director, Medical Affairs at Astellas Pharma Canada.
Proposals for the 2017 CUA Astellas Research Grant Program are now being accepted. The submission deadline is February 28th, 2017. Additional details regarding the eligibility criteria and application process can be found on both the CUA and Astellas websites:
About the Canadian Urological Association (CUA)
The CUA Mission is to represent and provide a voice for all Canadian urologists and to foster dedication of all members of the profession toward ensuring the highest possible standard of urologic care for Canadians.
The goals of the CUA are to:
More information about CUA can be found at www.cua.org
About Astellas Pharma Inc.
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en
About Astellas Pharma Canada, Inc.
Astellas Pharma Canada, Inc., headquartered in Markham, ON, is a Canadian affiliate of Tokyo-based Astellas Pharma Inc. In Canada, Astellas has an intense commercial focus on four therapeutic areas – Urology, Immunology, Infectious Disease, and Oncology. For more information about Astellas Pharma Canada, Inc., please visit the corporate website: www.astellas.ca
SOURCE Astellas Pharma Canada, Inc.PR Newswire
Last updated on: 18/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.